Savara’s (SVRA) Market Outperform Rating Reaffirmed at JMP Securities

JMP Securities restated their market outperform rating on shares of Savara (NASDAQ:SVRA) in a report issued on Thursday,Benzinga reports. They currently have a $9.00 price target on the stock.

Several other analysts have also issued reports on the company. Evercore ISI reaffirmed an “in-line” rating and issued a $5.00 target price (down previously from $7.00) on shares of Savara in a research note on Wednesday, November 13th. HC Wainwright cut their target price on Savara from $10.00 to $6.00 and set a “buy” rating for the company in a research note on Wednesday, November 13th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $9.86.

Savara Stock Performance

Shares of NASDAQ:SVRA remained flat at $3.23 during mid-day trading on Thursday. 248,236 shares of the company were exchanged, compared to its average volume of 1,267,257. The company has a 50 day simple moving average of $3.48 and a 200-day simple moving average of $3.99. The company has a current ratio of 17.70, a quick ratio of 17.70 and a debt-to-equity ratio of 0.13. Savara has a 52 week low of $2.82 and a 52 week high of $5.70. The stock has a market capitalization of $554.33 million, a price-to-earnings ratio of -7.51 and a beta of 0.92.

Savara (NASDAQ:SVRA) last issued its earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.11). On average, research analysts anticipate that Savara will post -0.45 EPS for the current fiscal year.

Insider Activity at Savara

In related news, Director Joseph S. Mccracken purchased 20,000 shares of Savara stock in a transaction dated Tuesday, November 19th. The stock was purchased at an average cost of $2.95 per share, for a total transaction of $59,000.00. Following the completion of the acquisition, the director now directly owns 210,837 shares of the company’s stock, valued at $621,969.15. The trade was a 10.48 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Matthew Pauls sold 54,702 shares of the firm’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $3.31, for a total value of $181,063.62. Following the transaction, the chief executive officer now owns 1,536,379 shares of the company’s stock, valued at $5,085,414.49. The trade was a 3.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.13% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Savara

Several institutional investors have recently modified their holdings of the business. Choreo LLC bought a new position in shares of Savara in the second quarter worth about $59,000. DRW Securities LLC bought a new stake in Savara in the 2nd quarter worth approximately $62,000. Virtu Financial LLC purchased a new position in shares of Savara in the 3rd quarter worth approximately $67,000. Principal Financial Group Inc. boosted its holdings in shares of Savara by 64.4% in the 2nd quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock worth $72,000 after purchasing an additional 6,973 shares during the period. Finally, Profund Advisors LLC purchased a new position in shares of Savara in the 2nd quarter worth approximately $105,000. 87.93% of the stock is owned by hedge funds and other institutional investors.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.